Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simtuzumab dose-ranging phase 2b trial in primary sclerosing cholangitis
NL-OMON40200Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Mar 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of simtuzumab in Primary Sclerosing Cholangitis (PSC) and hepatic fibrosis (3 arms), sponsored by Gilead Sciences. Primary endpoint: Change from baseline in morphometric quantitative collagen on liver biopsy at week 96. Started Mar 2014; status: active, not recruiting.
02
Drugs
simtuzumab
03
Conditions
Primary Sclerosing Cholangitis (PSC)hepatic fibrosis
Beyond the preview
Go deeper on NL-OMON40200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40200.